London-based pan-emerging markets private equity firm Actis has made a bid for Adcock Ingram, South Africa's second-biggest pharmaceutical company, Business Day reported, quoting an unnamed source close to the deal. Actis has declined to comment. Earlier this month, Adcock said that it was evaluating non-binding proposals from unnamed bidders that could lead to the acquisition of 100% of the company or a controlling stake in it.
Adcock’s board turned down last month a ZAR 6.2bn (EUR 501.4mn) offer for a 60% stake from South African industrial conglomerate Bidvest Group, saying Bidvest’s proposal was not made correctly. It has not received a new proposal from Bidvest, but Bidvest has said it hoped that Adcock shareholders would be given the opportunity to vote on its previous offer, turning to a potential hostile bid.
JSE-listed Adcock Ingram has been underperforming since 2008, when it was unbundled from South Africa's biggest foods maker Tiger Brands, and analysts have described it as a long-overdue takeover target.
A Zimbabwean research entity plans to build a towering bronze and stone monument honouring the former Soviet Union's victory over Nazi Germany in the Second World War. Kwame Muzawazi, the founder ... more
The Nigerian government is poised to greenlight ExxonMobil's $1.28bn asset sale to Seplat Energy within the next two weeks, pending resolution on critical issues related to decommissioning and host ... more
Atlantic Lithium Ltd., an African-focused lithium exploration and development company targeting to deliver Ghana's first lithium mine, has been approved to list on the Ghana Stock Exchange (GSE), ... more